Table 3.
Vorinostat, capecitabine, and ionizing radiation - tumor growth delay
| Treatment groups | TGD2x(days) | Compared to (group) | p-value |
|---|---|---|---|
|
HCT116 |
|
|
|
| IR |
5.68 ± 8.5 |
C |
0.03 |
| CAP |
2.68 ± 2.4 |
C |
0.001 |
| VOR |
0.24 ±1.9 |
C |
0.7 |
| CAP-IR |
5.46 ± 6.1 |
IR |
0.9 |
| VOR-IR |
20.06 ± 15.1 |
IR |
0.01 |
| VOR-CAP-IR |
18.99 ± 7.3 |
CAP-IR |
<0.001 |
|
SW620 |
|
|
|
| IR |
1.40 ± 2.2 |
C |
0.06 |
| CAP |
0.14 ± 1.8 |
C |
0.8 |
| VOR |
0.88 ± 1.9 |
C |
0.2 |
| CAP-IR |
2.53 ± 3.1 |
IR |
0.3 |
| VOR-IR |
2.8 ± 2.6 |
IR |
0.2 |
| VOR-CAP-IR | 5.78 ± 3.9 | CAP-IR | 0.03 |
TGD2x = tumor growth delay at 2-fold increase of relative tumor volume; IR = ionizing radiation;
C = control; CAP = capecitabine; VOR = vorinostat; CAP-IR = capecitabine and IR;
VOR-IR = vorinostat and IR; VOR-CAP-IR = vorinostat, capecitabine and IR.